Liquid chromatography-high resolution mass spectrometry (LC-HRMS) determination of stimulants, anorectic drugs and phosphodiesterase 5 inhibitors (PDE5I) in food supplements

Journal of Pharmaceutical and Biomedical Analysis

Volumn 106, Issue , 2015, Pages 144-152

  Strano Rossi, Sabina ^a   Odoardi, Sara ^a   Castrignanò, Erika ^a   Serpelloni, Giovanni ^b   Chiarotti, Marcello ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Anti Drug Policies   (Italy)

Author keywords

Anorectics; LC HRMS; Nutritional supplements; PdE5Is; Stimulants

Indexed keywords

ANOREXIGENIC AGENT; BENFLUOREX; CAFFEINE; CENTRAL STIMULANT AGENT; CLENBUTEROL; EPHEDRINE; FENCANFAMINE; FENFLURAMINE; MEPHENTERMINE; PHENDIMETRAZINE; PHENMETRAZINE; PHENTERMINE; PHOSPHODIESTERASE V INHIBITOR; PSEUDOEPHEDRINE; SIBUTRAMINE; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ACCURACY; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DETERMINATION; DRUG IDENTIFICATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OPTICAL RESOLUTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANALYSIS; DRUG LABELING; PROCEDURES; REPRODUCIBILITY;

APPETITE DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, LIQUID; DIETARY SUPPLEMENTS; DRUG LABELING; LIMIT OF DETECTION; MASS SPECTROMETRY; PHOSPHODIESTERASE 5 INHIBITORS; REPRODUCIBILITY OF RESULTS;

EID: 84923320201     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.06.011     Document Type: Article

References (21)

1. Directive 2002/46/EC, (accessed 20.04.14). http://ec.europa.eu/food/food/labellingnutrition/supplements/index_en.htm.
2. Directive 2010/84/EU, (accessed 20.04.14). http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf.
3. Parr M.K., Koehler K., Geyer H., Guddat S., Schanzer W. Clenbuterol marketed as dietary supplement. Biomed. Chromatogr. 2008, 22:298-300.
4. Jung J., Hermanns-Clausen M., Weinmann W. Anorectic sibutramine detected in a Chinese herbal drug for weight loss. Forensic Sci. Int. 2006, 161:221-222.
5. Vidal C., Quandte S. Identification of a sibutramine-metabolite in patient urine after intake of a "pure herbal" Chinese slimming product. Ther. Drug Monit. 2006, 28:690-692.
6. Zou P., Oh S.S., Kiang K.H., Low M.Y., Bloodworth B.C. Detection of sibutramine, its two metabolites and one analogue in a herbal product for weight loss by liquid chromatography triple quadrupole mass spectrometry and time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:614-618.
7. Kim H.J., Lee J.H., Park H.J., Cho S.H., Cho S., Kim W.S. Monitoring of 29 weight loss compounds in foods and dietary supplements by LC-MS/MS. Food Addit. Contam. A: Chem. Anal. Control Expo. Risk Assess. 2014, 31:777-783.
8. Delbeke F.T. Nutritional supplements and doping. Biomedical Side Effects of Doping 2001, 155-161. Cologne. C. Peters, T. Schulz, H. Michna (Eds.).
9. de Hon O., Coumans B. The continuing story of nutritional supplements and doping infractions. Br. J. Sports Med. 2007, 41:800-805. discussion 805.
10. Man C.N., Nor N.M., Lajis R., Harn G.L. Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column. J. Chromatogr. A 2009, 1216:8426-8430.
11. Shi F., Guo C., Gong L., Li J., Dong P., Zhang J., Cui P., Jiang S., Zhao Y., Zeng S. Application of a high resolution benchtop quadrupole-Orbitrap mass spectrometry for the rapid screening, confirmation and quantification of illegal adulterated phosphodiesterase-5 inhibitors in herbal medicines and dietary supplements. J. Chromatogr. A. 2014, 1344:91-98.
12. Lee H.M., Lee B.J. A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method. Food Addit. Contam. A: Chem. Anal. Control Expo. Risk Assess. 2011, 28:396-407.
13. Gryniewicz C.M., Reepmeyer J.C., Kauffman J.F., Buhse L.F. Detection of undeclared erectile dysfunction drugs and analogues in dietary supplements by ion mobility spectrometry. J. Pharm. Biomed. Anal. 2009, 49:601-606.
14. Venhuis B.J., de Kaste D. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J. Pharm. Biomed. Anal. 2012, 69:196-208.
15. Wada List of Prohibited Substances and Methods 2014, http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2014/WADA-prohibited-list-2014-EN.pdf (accessed 20.04.14).
16. Martello S., Felli M., Chiarotti M. Survey of nutritional supplements for selected illegal anabolic steroids and ephedrine using LC-MS/MS and GC-MS methods, respectively. Food Addit. Contam. 2007, 24:258-265.
17. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
18. Scheen A.J. Cardiovascular risk-benefit profile of sibutramine. Am. J. Cardiovasc. Drugs 2010, 10:321-334.
19. Tribouilloy C., Marechaux S., Jobic Y., Jeu A., Ederhy S., Donal E., Reant P., Arnalsteen E., Boulanger J., Garban T., Ennezat P.V., Andrejak M., Rusinaru D. Frequency of drug-induced valvular heart disease in patients previously exposed to benfluorex: a multicentre prospective study. Eur. Heart J. 2013, 34:3580-3587.
20. Andrejak M., Tribouilloy C. Drug-induced valvular heart disease: an update. Arch. Cardiovasc. Dis. 2013, 106:333-339.
21. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simonneau G., Begaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. 1996, 335:609-616.